Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7954118 | 1.00 | ALDH1A1 (0.51) | ALDH1A1GLATP53TSHRHIF1A | |
| SCHEMBL6605556 | 1.00 | ALDH1A1 (0.51) | ALDH1A1GLATP53TSHRHIF1A | |
| SCHEMBL729501 | 0.80 | ALDH1A1 (0.65) | ALDH1A1GLATP53TSHRHIF1A | |
| SCHEMBL9538716 | 0.77 | ALDH1A1 (0.49) | ALDH1A1GLATP53TSHRHIF1A | |
| SCHEMBL18812765 | 0.75 | ALDH1A1 (0.67) | ALDH1A1GLATP53TSHRHIF1A | |
| SCHEMBL5026215 | 0.74 | ALDH1A1 (0.62) | ALDH1A1GLATP53TSHRHIF1A | |
| SCHEMBL5433989 | 0.74 | ALDH1A1 (0.62) | ALDH1A1GLATP53TSHRHIF1A | |
| SCHEMBL31120482 | 0.74 | ALDH1A1 (0.57) | ALDH1A1GLATP53TSHRHIF1A | |
| SCHEMBL29402954 | 0.74 | ALDH1A1 (0.62) | ALDH1A1GLATP53TSHRHIF1A | |
| SCHEMBL93314 | 0.74 | ALDH1A1 (0.62) | ALDH1A1GLATP53TSHRHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6784180-B2 | INHIBITING THE REUPTAKE OF SEROTONIN AND ANTAGONIZING THE 5-HT1A RECEPTOR; AS ANTIDEPRESSANT OR TO POTENTIATE EFFECTS OF ANOTHER SSRI | ELI LILLY AND COMPANY | 2004-08-31 | — | — | US | disclosed |
| EP-1250336-B1 | PIPERIDINE DERIVATIVES AND THEIR USE AS SEROTONIN RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2004-05-12 | — | — | EP | disclosed |
| US-20030225281-A1 | Piperidines derivatives and their use as serotonin receptor antagonists | ELI LILLY AND COMPANY | 2003-12-04 | — | — | US | disclosed |
| EP-1250336-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS SEROTONIN RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2002-10-23 | — | — | EP | disclosed |
| WO-2001046179-A1 | PIPERIDINE DERIVATIVES AND THEIR USE AS SEROTONIN RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2001-06-28 | — | — | WO | disclosed |
| US-6242450-B1 | SUBSTITUTED PIPERIDINES | ELI LILLY AND COMPANY | 2001-06-05 | — | — | US | disclosed |
| WO-2000006082-A2 | TREATMENT OF ANXIETY DISORDERS | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| WO-2000006166-A1 | 5-HT1F ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| EP-0976746-A1 | 5-HT1F antagonists | ELI LILLY AND COMPANY (US) | 2000-02-02 | — | — | EP | disclosed |
| EP-0976747-A2 | Use of 5HT-1F receptor antagonists for treating anxiety disorders | ELI LILLY AND COMPANY (US) | 2000-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225281-A1 | Piperidines derivatives and their use as serotonin receptor antagonists | HTR1A, HTR1D, HTR5A | ALDH1A1 327/4885GLA 3742/4885TP53 4545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.